コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 and immune activation occurs locally, in the oesophagus.
2 ar smooth-muscle fibres within the abdominal oesophagus.
3 ween atopy and malignancy the lung, skin and oesophagus.
4 transport it back to the throat and into the oesophagus.
5 ed by approximately 70% compared with normal oesophagus.
6 in the perception of pain originating in the oesophagus.
7 risk of neoplastic progression in Barrett's oesophagus.
8 g results in improved detection of Barrett's oesophagus.
9 orded pressures in the hypopharynx and upper oesophagus.
10 stinal metaplasia and dysplasia in Barrett's oesophagus.
11 othelial growth factors (VEGFs) in Barrett's oesophagus.
12 ces and transports the particles towards the oesophagus.
13 of particle transport from the rakers to the oesophagus.
14 might prevent the precursor lesion Barrett's oesophagus.
15 a pectoris but generally originates from the oesophagus.
16 Acid was infused into the lower oesophagus.
17 eral cortical projections to the pharynx and oesophagus.
18 which receive vagal afferent input from the oesophagus.
19 afferent feedback from the face, pharynx and oesophagus.
20 visit, and 50.7% were never biopsied in the oesophagus.
21 - a donut-shaped brain organised around the oesophagus.
22 is and monitoring of patients with Barrett's Oesophagus.
23 n of cancers of the oral cavity, pharynx and oesophagus.
24 esophageal adenocarcinoma (EAC) or Barrett's oesophagus.
25 TFF3) is a non-endoscopic test for Barrett's oesophagus.
26 eventing reflux of gastric contents into the oesophagus.
27 ion of EoE is spontaneous perforation of the oesophagus.
28 sure zone that prevents acid reflux into the oesophagus.
29 ng behaviours were present within the distal oesophagus.
30 actors to prioritise endoscopy for Barrett's oesophagus.
31 t occurs during the development of Barrett's oesophagus.
32 n for multi-layered epithelium and Barrett's oesophagus.
33 ndoscopic therapies for dysplastic Barrett's oesophagus.
34 and overtreatment in patients with Barrett's oesophagus.
35 ated and reliable in patients with Barrett's oesophagus.
36 in the lung, four in the skin and one in the oesophagus.
37 that are specific to patients with Barrett's oesophagus.
38 tructural and functional regeneration of the oesophagus.
39 n whose expression is highly enriched in the oesophagus.
40 risk factor for the development of Barrett's oesophagus.
41 mas (9; pancreatic (3), small-cell lung (4), oesophagus (1), endometrium (1)), adenocarcinomas (6; lu
42 ttributable cancer cases, and cancers of the oesophagus (189 700 cases [110 900-274 600]), liver (154
43 3 (TFF3), can be used to diagnose Barrett's oesophagus, a precursor condition to oesophageal adenoca
44 d precursor lesions in people with Barrett's oesophagus--a metaplastic disorder that confers a high r
45 ual care group were diagnosed with Barrett's oesophagus (absolute difference 18.3 per 1000 person-yea
47 c, histologically confirmed carcinoma of the oesophagus (adenocarcinoma, squamous-cell, or undifferen
49 ample comprised 6167 patients with Barrett's oesophagus and 4112 individuals with oesophageal adenoca
50 up-regulated in the progression of Barrett's oesophagus and beta-catenin mediated transcription of c-
52 nfined to people with adenocarcinomas of the oesophagus and gastro-oesophageal junction (Siewert type
54 emerging chronic inflammatory disease of the oesophagus and is clinically characterized by upper gast
55 s necessary for the development of Barrett's oesophagus and its progression to cancer, and new stride
56 from dysfunction at the mouth, pharynx, and oesophagus and may predispose individuals to aspiration
58 his situation is exacerbated both in Barrett oesophagus and OAC by a historical clinical reliance on
59 of research on the heterogeneity of Barrett oesophagus and OAC, summarizing our knowledge of the fac
60 the number of known risk loci for Barrett's oesophagus and oesophageal adenocarcinoma and revealed n
61 genome-wide association studies of Barrett's oesophagus and oesophageal adenocarcinoma available in P
62 progression of healthy epithelial, Barrett's oesophagus and oesophageal adenocarcinoma cell lines.
63 tium investigating the genetics of Barrett's oesophagus and oesophageal adenocarcinoma, we aimed to i
64 ey molecules in the development of Barrett's oesophagus and oesophageal adenocarcinoma, which might e
66 ress the devices during delivery through the oesophagus and other narrow orifices in the digestive sy
69 types of surgery used to treat cancer of the oesophagus and summarise the available data about their
70 ting rhythmic, phasic activity in the distal oesophagus and that Ca(2+) release occurs in ICC-IM via
71 cinomas (SqCCs) of the lungs, head and neck, oesophagus, and cervix account for up to 30% of cancer d
72 nt of non-melanoma skin cancer and Barrett's oesophagus, and improved photosensitising drugs are in d
74 cancers of the oral cavity, pharynx, larynx, oesophagus, and liver, and causes a small increase in th
75 of several complex tissues such as trachea, oesophagus, and skeletal muscle in animal models and hum
76 osed lower oesophagus, the non-exposed upper oesophagus, and the cutaneous area of pain referral, bef
77 ce) suggests immune activation occurs in the oesophagus, and the relative lack of langerhans cells (C
78 orts to screen patients at risk of Barrett's oesophagus, and whether such efforts avert cancer death.
79 al nociceptive-like fibres in the guinea-pig oesophagus are derived from two embryonically distinct s
80 structures such as the respiratory tract and oesophagus are diverse, comprising several subtypes of f
82 ium (believed to be a precursor of Barrett's oesophagus) are both characterized by the expansion of t
83 a (OAC) and its precursor condition, Barrett oesophagus, are characterized by phenotypic and molecula
84 ns has been demonstrated in the human distal oesophagus as well as in the dog proximal LES but is abs
87 equency of ecDNA increased between Barrett's-oesophagus-associated early-stage (24%) and late-stage (
88 imary outcome was the diagnosis of Barrett's oesophagus at 12 months after enrolment, expressed as a
90 (EAC) and the pre-invasive tissue, Barrett's oesophagus (BE), provide an ideal example in which to ob
93 e is recommended for patients with Barrett's oesophagus because, although the progression risk is low
97 hanges that have been described in Barrett's oesophagus can be categorised according to the predomina
99 ally invasive abdominal technique, the lower oesophagus can be mobilised to the mediastinum without p
100 The precancerous lesion known as Barrett's oesophagus can evolve to oesophageal adenocarcinoma in d
102 samples and evaluated in relation to HNC and oesophagus cancer risk and post-diagnosis all-cause mort
103 Achalasia is a rare motility disorder of the oesophagus characterised by loss of enteric neurons lead
104 Obesity increases the risk of cancers in the oesophagus, colorectum, breast, endometrium, and kidney.
105 uctions in HRQoL scores related to Barrett's oesophagus compared with controls from the general popul
107 The vagal nociceptive-like fibres in the oesophagus comprise two distinct subtypes dictated by th
108 fficacy of a dedicated service for Barrett's oesophagus, cost-effectiveness and appropriateness of cu
109 inoma (OAC) or its precursor state Barrett's oesophagus coupled with open chromatin maps to identify
110 However, only a few patients with Barrett's oesophagus develop adenocarcinoma, which complicates cli
112 ast 18 years with a non-dysplastic Barrett's oesophagus diagnosis at their last endoscopy who were un
113 ation in the lung (asthma), skin (eczema) or oesophagus (eosinophilic oesophagitis; EoE) and cancer a
115 age, in the breast, colorectum, endometrium, oesophagus, extrahepatic bile duct, gallbladder, head an
116 essed in all tissues examined, including the oesophagus, eye, liver, intestine, posterior and anterio
117 infusion, their pain threshold in the upper oesophagus fell further and for longer (mean fall in are
120 electrical stimuli applied to the pharynx or oesophagus had no effect on the response to cortical sti
121 y of squamous cell and adenocarcinoma of the oesophagus has diverged over the past several decades, w
122 pic treatment of early neoplastic lesions in oesophagus has evolved as a valid and less invasive alte
123 ffuse oesophageal spasm and hypercontracting oesophagus, have no well defined pathology and could rep
124 in microbial communities occur in the lower oesophagus in Barrett's carcinogenesis, which can be det
125 in microbial communities occur in the lower oesophagus in Barrett's carcinogenesis, which can be det
132 lusive: no model completely mimics Barrett's oesophagus in terms of the presence of intestinal goblet
133 s and extracellular matrix to regenerate the oesophagus in vivo in a human being to re-establish swal
134 n mice causes hyperplasia selectively in the oesophagus, in association with increased cell prolifera
135 the major cell and tissue components of the oesophagus including functional epithelium, muscle fibre
141 f homeostasis in the epithelium of the mouse oesophagus is guided by the progressive build-up of mech
145 tion in which the squamous epithelium of the oesophagus is replaced by columnar epithelium as an adap
150 pheral arterial disease, epilepsy, Barrett's oesophagus, ischaemic stroke, unstable angina and asthma
151 ry-level HDI for cancers of the oral cavity, oesophagus, liver, thyroid, and for Hodgkin lymphoma.
152 thy volunteers, acid infusion into the lower oesophagus lowered the pain threshold in the upper oesop
153 2.78, 95% CI 2.69-2.87), but cancers of the oesophagus, lung, stomach, myeloma, and lymphoma were as
154 ge achalasia with a dilated, non-functioning oesophagus may require oesophagectomy or enteral feeding
155 agus lowered the pain threshold in the upper oesophagus (mean decrease 18.2% [95% CI 10.4 to 26.0]; p
158 nts were diagnosed with dysplastic Barrett's oesophagus (n=4) or stage I oesophago-gastric cancer (n=
159 n-dysplastic [n=24] and dysplastic Barrett's oesophagus [n=23], and oesophageal adenocarcinoma [n=19]
162 stologically confirmed adenocarcinoma of the oesophagus, oesophagogastric junction, or stomach that h
163 ylidene-2'-deoxyguanosine were higher in the oesophagus of Aldh2-knockout mice than in wild-type mice
164 hypothalamus, pituitary, pancreas, lungs and oesophagus of mouse embryos using in situ hybridization.
169 w risk loci associated with either Barrett's oesophagus or oesophageal adenocarcinoma, within or near
170 nts were diagnosed with dysplastic Barrett's oesophagus or stage I gastro-oesophageal junction cancer
171 lly significant higher odds of cancer of the oesophagus (OR 1.83; 95% CI 1.34-2.49; p = 1.31 x 10-4),
172 ence of complex tissues such as the trachea, oesophagus, or skeletal muscle have few therapeutic opti
173 endometrium, kidney, liver, lung, lymphoid, oesophagus, ovary, pancreas, skin, soft tissue and thyro
176 rade dysplasia in columnar-lined (Barrett's) oesophagus presents a difficult therapeutic dilemma.
178 from 86 patients representing the Barrett's oesophagus progression sequence (normal squamous control
181 ive stress-strain relationships of the human oesophagus resemble those of other soft biological tissu
185 emical techniques with retrogradely labelled oesophagus-specific neurones and performing extracellula
186 ary, cervix, endometrium, bladder, prostate, oesophagus, squamous cell carcinoma of the head and neck
187 , including most of those originating in the oesophagus, stomach, biliary tract and pancreas, but not
190 00 countries and territories for 11 cancers (oesophagus, stomach, colon, rectum, anus, liver, pancrea
191 r patients diagnosed with one of 11 cancers (oesophagus, stomach, colon, rectum, anus, liver, pancrea
192 global cancer survival for 11 cancer sites (oesophagus, stomach, colon, rectum, anus, liver, pancrea
193 rway, and the UK) for seven sites of cancer (oesophagus, stomach, colon, rectum, pancreas, lung, and
194 ted with an increased risk of cancers of the oesophagus, stomach, larynx, lung, and urinary bladder.
195 agnosis for eight cancer types (oral cavity, oesophagus, stomach, larynx, lung, liver, non-Hodgkin ly
197 is a metaplastic change of the lining of the oesophagus, such that the normal squamous epithelium is
198 hese data included 206 biopsies in Barrett's oesophagus surveillance and EAC cohorts from Cambridge U
201 were monitored within the acid-exposed lower oesophagus, the non-exposed upper oesophagus, and the cu
202 alterations of RA biosynthesis in Barrett's oesophagus, the precursor lesion to oesophageal adenocar
204 inct stages of this malignancy, from Barrett Oesophagus to primary tumours and advanced metastatic di
206 ed for the growth and differentiation of the oesophagus, trachea and lung, and suggest that mutations
207 mechanical stress experienced by the growing oesophagus triggers the emergence of a bright Kruppel-li
208 ohort study (BEST2), patients with Barrett's oesophagus underwent the Cytosponge test before their su
210 lls of non-skin origin (e.g. that of cornea, oesophagus, vagina, bladder, prostate) that express the
211 sic contractile activity in the mouse distal oesophagus was also inhibited by ANO1 and VDCC antagonis
212 stents were removed after 3.5 years and the oesophagus was assessed by endoscopy, biopsy, endoscopic
213 d early steps in the initiation of Barrett's oesophagus, we assessed the expression, location and fun
214 ordings from the isolated vagally innervated oesophagus, we show that in the guinea-pig, the vagus ne
216 latency reflex responses in the pharynx and oesophagus, were used to condition the cortical response
217 in stratified epithelia, most notably in the oesophagus where the Nanog promoter is hypomethylated.
220 the guinea-pig, the vagus nerves supply the oesophagus with a large population of nociceptive-like a
222 that the vagus nerves supply the guinea-pig oesophagus with nociceptors in addition to tension mecha
223 ntenance of the structural morphology of the oesophagus with off-the-shelf non-biological scaffold an
224 al we saw full-thickness regeneration of the oesophagus with stratified squamous epithelium, a normal
225 having endoscopic surveillance for Barrett's oesophagus (with intestinal metaplasia confirmed by TFF3